Baricitinib,
does it really help with Reduced 28-day mortality in patients hospitalized with COVID-19?
research showsThe grade is B. In RECOVERY, 28-day mortality was 514/4,148 (12.4%) with baricitinib versus 546/4,008 (13.6%) with usual care, age-adjusted rate ratio 0.87 (95% CI 0.77 to 0.99). Because 95% received corticosteroids, this mainly supports add-on use in hospitalized patients requiring oxygen while receiving steroids.
ads claimThis was an add-on effect over contemporaneous standard care, especially corticosteroids. Verdict 685 is B with 75 points for severe alopecia areata hair regrowth, a different indication.
Useful facts when choosing a product
- RECOVERY added baricitinib 4 mg for up to 10 days or discharge.
- COV-BARRIER used 4 mg for up to 14 days or discharge against matched placebo.
- The full RECOVERY collaborator appendix was not completely matched against the COV-BARRIER investigator list.
- In COV-BARRIER, infections were 119/750 (15.9%) versus 123/752 (16.4%), serious infections 64/750 (8.5%) versus 74/752 (9.8%), and venous thromboembolism 20/750 (2.7%) versus 19/752 (2.5%).
- RECOVERY did not report between-arm absolute counts for infection or thrombosis; these could not be confirmed.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.baricitinib.UNK.mortality-hospitalized-with-covid-19.reduce.MULTIUnknown > Baricitinib > Unknown > mortality hospitalized with COVID-19 > Reduction claim > Multiple: primary unresolved
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Both trials effectively compared adding baricitinib to contemporaneous standard care; RECOVERY described its control as “usual standard of care alone.” The complete RECOVERY collaborator appendix could not be matched against the COV-BARRIER investigator list, so author overlap was not determined. RECOVERY listed “UK Research and Innovation (Medical Research Council) and National Institute of Health Research” and no manufacturer funding. COV-BARRIER listed “Eli Lilly and Company,” which is manufacturer funding.
Why this is classified as B (76)
A large publicly funded randomized trial demonstrated a meaningful reduction in an objective mortality endpoint without an avoidable major design defect. Because complete independent replication could not be established, the result is B with 76 points.
Counterpoint. COV-BARRIER supported mortality benefit, but its primary progression composite was null and it was manufacturer funded.
Rejudgment record. Cross-check applied — Absolute mortality, steroid co-treatment, oxygen support, controls, funding, and the limits of author-list verification were checked
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (B).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced 28-day mortality | B | Significant for the RECOVERY primary outcome. |
| Infection and thrombosis harm | D | No significant increase appeared in the short COVID-19 trials. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| RECOVERY Collaborative Group 2022 | Multicenter randomized open-label platform trial | 8,156 randomized and analyzed by intention to treat (4,148/4,008) | UK Research and Innovation (Medical Research Council) and National Institute of Health Research; no manufacturer funding listed | Primary outcome: 28-day all-cause mortality | 514/4,148 (12.4%) vs 546/4,008 (13.6%); age-adjusted RR 0.87 (95% CI 0.77 to 0.99); between-arm absolute infection and thrombosis counts could not be confirmed | Decisive publicly funded evidence |
| Marconi et al. 2021 COV-BARRIER | Double-blind placebo-controlled phase 3 randomized trial | 1,525 randomized | Eli Lilly and Company (manufacturer funding) | Primary progression composite; 28-day mortality was secondary | Primary 27.8% vs 30.5%, OR 0.85 (0.67 to 1.08); mortality 62/764 (8.1%) vs 100/761 (13.1%), HR 0.57 (0.41 to 0.78) | Manufacturer-funded supportive evidence; full investigator matching unfinished |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-08-07).
Final verification and publication gate: Codex · Evidence date: 2026-08-07 · Corrections: none
Cite this verdict
[Chamgap] Baricitinib x reduced mortality in hospitalized COVID-19 — Evidence Grade B·76. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/baricitinib-hospitalized-covid-19-mortality/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.